This section provides a brief overview of our most popular immuno-oncology biomarkers. We have developed a non-invasive method to look at activation of T-cells, macrophages and neutrophils. Understand pharmacodynamics, Mode of Action and efficacy non-invasively.
Therefore, it is important to identify patients with a T-cell permissive tumor microenvironment.
Patients with a severe desmoplastic reaction have a significantly reduced response to checkpoint inhibitor treatment due to fibrotic involvement of the tissue. We can pinpoint patients with a low desmoplastic reaction, and thereby patients that are likely to survive due to correct treatment. Read below about how you can utilize that in your clinical program.
Nordic Bioscience’s collagen biomarkers can be used as cancer-associated fibroblast (CAF) biomarkers to identify specific CAF subtypes and patients who have specific CAF subtypes. These biomarkers can be applied as operational biomarkers for drug development targeting CAFs.
Nordic Bioscience integrates innovative translational models with the Nordic ProteinFingerPrint Technology™ to translate findings efficiently. By using the same biomarkers throughout various clinical development stages, they create a seamless link between preclinical models and clinical applications. This strategically chosen development pathway significantly enhances the efficiency of drug development pipelines.
Nordic Bioscience’s assays, products, and services are for research use only and are not intended for medical or diagnostic purposes.
